company background image
6033

Beijing Wantai Biological Pharmacy Enterprise SHSE:603392 Stock Report

Last Price

CN¥155.44

Market Cap

CN¥136.8b

7D

3.4%

1Y

-8.7%

Updated

03 Jul, 2022

Data

Company Financials +
603392 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth6/6
Past Performance5/6
Financial Health6/6
Dividends0/6

603392 Stock Overview

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Beijing Wantai Biological Pharmacy Enterprise Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Beijing Wantai Biological Pharmacy Enterprise
Historical stock prices
Current Share PriceCN¥155.44
52 Week HighCN¥206.74
52 Week LowCN¥118.54
Beta2.95
1 Month Change23.88%
3 Month Change-18.64%
1 Year Change-8.74%
3 Year Changen/a
5 Year Changen/a
Change since IPO2,404.31%

Recent News & Updates

Shareholder Returns

603392CN BiotechsCN Market
7D3.4%3.7%1.3%
1Y-8.7%-31.4%-6.8%

Return vs Industry: 603392 exceeded the CN Biotechs industry which returned -31.4% over the past year.

Return vs Market: 603392 underperformed the CN Market which returned -6.8% over the past year.

Price Volatility

Is 603392's price volatile compared to industry and market?
603392 volatility
603392 Average Weekly Movement7.9%
Biotechs Industry Average Movement7.0%
Market Average Movement7.2%
10% most volatile stocks in CN Market10.2%
10% least volatile stocks in CN Market5.0%

Stable Share Price: 603392 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 603392's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19913,103Zixin Qiuhttps://www.ystwt.com

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. researches, develops, produces, distributes, and sells infectious disease diagnostic reagents and vaccines in China and internationally. The company provides COVID 19, HIV and HTLV, Hepatitis, EV-71, and Tuberculosis diagnostics test kits; Hepatitis C and Syphilis detection reagents; automated immunoassays; ELISA kits and rapid tests for infectious disease diagnostics; chemiluminescence and clinical chemistry reagents; immunodiagnostic reagents; and Hepatitis E and human papillomavirus vaccines.

Beijing Wantai Biological Pharmacy Enterprise Fundamentals Summary

How do Beijing Wantai Biological Pharmacy Enterprise's earnings and revenue compare to its market cap?
603392 fundamental statistics
Market CapCN¥136.82b
Earnings (TTM)CN¥3.06b
Revenue (TTM)CN¥8.10b

44.7x

P/E Ratio

16.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
603392 income statement (TTM)
RevenueCN¥8.10b
Cost of RevenueCN¥1.05b
Gross ProfitCN¥7.05b
Other ExpensesCN¥3.99b
EarningsCN¥3.06b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)3.48
Gross Margin87.05%
Net Profit Margin37.83%
Debt/Equity Ratio4.9%

How did 603392 perform over the long term?

See historical performance and comparison

Dividends

0.09%

Current Dividend Yield

4%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is 603392 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 603392?

Other financial metrics that can be useful for relative valuation.

603392 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue16.7x
Enterprise Value/EBITDA37.4x
PEG Ratio1.7x

Price to Earnings Ratio vs Peers

How does 603392's PE Ratio compare to its peers?

603392 PE Ratio vs Peers
The above table shows the PE ratio for 603392 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average99x
300122 Chongqing Zhifei Biological Products
16.3x11.9%CN¥182.3b
300142 Walvax Biotechnology
179.1xn/aCN¥77.8b
688363 Bloomage BioTechnology
80.8x28.5%CN¥67.1b
300896 Imeik Technology DevelopmentLtd
119.8x37.8%CN¥127.9b
603392 Beijing Wantai Biological Pharmacy Enterprise
44.7x26.7%CN¥136.8b

Price-To-Earnings vs Peers: 603392 is good value based on its Price-To-Earnings Ratio (44.7x) compared to the peer average (99x).


Price to Earnings Ratio vs Industry

How does 603392's PE Ratio compare vs other companies in the CN Biotechs Industry?

Price-To-Earnings vs Industry: 603392 is expensive based on its Price-To-Earnings Ratio (44.7x) compared to the CN Biotechs industry average (40.3x)


Price to Earnings Ratio vs Fair Ratio

What is 603392's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

603392 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio44.7x
Fair PE Ratio42.6x

Price-To-Earnings vs Fair Ratio: 603392 is expensive based on its Price-To-Earnings Ratio (44.7x) compared to the estimated Fair Price-To-Earnings Ratio (42.6x).


Share Price vs Fair Value

What is the Fair Price of 603392 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 603392 (CN¥155.44) is trading below our estimate of fair value (CN¥248.87)

Significantly Below Fair Value: 603392 is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: 603392 is poor value based on its PEG Ratio (1.7x)


Discover undervalued companies

Future Growth

How is Beijing Wantai Biological Pharmacy Enterprise forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

6/6

Future Growth Score 6/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


26.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603392's forecast earnings growth (26.7% per year) is above the savings rate (3.2%).

Earnings vs Market: 603392's earnings (26.7% per year) are forecast to grow faster than the CN market (23.9% per year).

High Growth Earnings: 603392's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 603392's revenue (24.1% per year) is forecast to grow faster than the CN market (17.5% per year).

High Growth Revenue: 603392's revenue (24.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 603392's Return on Equity is forecast to be very high in 3 years time (41.7%).


Discover growth companies

Past Performance

How has Beijing Wantai Biological Pharmacy Enterprise performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


69.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 603392 has a high level of non-cash earnings.

Growing Profit Margin: 603392's current net profit margins (37.8%) are higher than last year (31.2%).


Past Earnings Growth Analysis

Earnings Trend: 603392's earnings have grown significantly by 69.5% per year over the past 5 years.

Accelerating Growth: 603392's earnings growth over the past year (242%) exceeds its 5-year average (69.5% per year).

Earnings vs Industry: 603392 earnings growth over the past year (242%) exceeded the Biotechs industry 11.3%.


Return on Equity

High ROE: 603392's Return on Equity (53.4%) is considered outstanding.


Discover strong past performing companies

Financial Health

How is Beijing Wantai Biological Pharmacy Enterprise's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 603392's short term assets (CN¥6.5B) exceed its short term liabilities (CN¥3.0B).

Long Term Liabilities: 603392's short term assets (CN¥6.5B) exceed its long term liabilities (CN¥168.3M).


Debt to Equity History and Analysis

Debt Level: 603392 has more cash than its total debt.

Reducing Debt: 603392's debt to equity ratio has reduced from 5.8% to 4.9% over the past 5 years.

Debt Coverage: 603392's debt is well covered by operating cash flow (708.7%).

Interest Coverage: 603392 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Beijing Wantai Biological Pharmacy Enterprise current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


0.089%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 603392's dividend (0.089%) isn’t notable compared to the bottom 25% of dividend payers in the CN market (0.48%).

High Dividend: 603392's dividend (0.089%) is low compared to the top 25% of dividend payers in the CN market (1.92%).


Stability and Growth of Payments

Stable Dividend: 603392 is not paying a notable dividend for the CN market, therefore no need to check if payments are stable.

Growing Dividend: 603392 is not paying a notable dividend for the CN market, therefore no need to check if payments are increasing.


Earnings Payout to Shareholders

Earnings Coverage: 603392 is not paying a notable dividend for the CN market.


Cash Payout to Shareholders

Cash Flow Coverage: 603392 is not paying a notable dividend for the CN market.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average board tenure


CEO

Zixin Qiu (59 yo)

no data

Tenure

CN¥1,657,400

Compensation

Mr. Zixin Qiu serves as the Chairman and General Manager at Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. and serves as its Board Secretary. He has been with Beijing Wantai Biological Pharmacy En...


Board Members

Experienced Board: 603392's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
  • Ticker: 603392
  • Exchange: SHSE
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CN¥136.820b
  • Shares outstanding: 880.21m
  • Website: https://www.ystwt.com

Number of Employees


Location

  • Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
  • No. 31 Kexueyuan Road
  • Changping District
  • Beijing
  • 102206
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/03 00:00
End of Day Share Price2022/07/01 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.